Nuformix

NFXHealthcare
0.1100GBX
4.76%
Market Cap
2.20M
Volume
7.6M
12% of avg
P/E Ratio
EPS (TTM)
Beta
0.97
Day Range
0.1025p - 0.1100p
52 Week Range
0.0400p0.1100p0.3000p
0.1100p

Upcoming Events

Q4 2025
Expected update on NXP002 development and potential partnerships
High Impact Event
December 2025
Potential need for additional funding round
High Impact Event
NFX
NEUTRAL

Nuformix Receives Orphan Drug Designation for NXP002 in IPF

The pharmaceutical company has received Orphan Drug Designation for its NXP002 programme in the treatment of idiopathic pulmonary fibrosis.

NFX
BAD

Nuformix Raises £210,000 Through Discounted Placing

The biotechnology company has raised £210,000 through a discounted share placing, signaling potential financial difficulties and low investor appetite.

NFX
NEUTRAL

Nuformix to Present NXP002 Data at American Thoracic Society Congress

The pharmaceutical company will present data on its NXP002 drug candidate at an upcoming medical conference.

NFX
BAD

Nuformix Reports Increased Losses and Cash Burn in Half-Year Results

The pre-revenue biotech firm reported widening losses and a shrinking cash balance, raising concerns about its ability to fund ongoing drug development programs without significant additional financing.

NFX
GOOD

Nuformix Receives Positive Opinion for Orphan Drug Designation in IPF

The pharmaceutical company has received positive opinion for Orphan Drug Designation from the European Medicines Agency for its IPF treatment, a significant regulatory milestone.

NFX
BAD

Nuformix Raises £13,200 Through Warrant Exercise, Shares Plunge

The biotechnology company has raised £13,200 through the exercise of warrants, issuing new shares at a 55% discount to the previous closing price. This large discount suggests low investor confidence and could signal financial distress.

NFX
BAD

Nuformix Raises £13,200 Through Warrant Exercise

The biotechnology company has raised £13,200 through the exercise of broker warrants, but at a 54.55% discount to the previous closing price, suggesting low market confidence.

NFX
GOOD

Nuformix Announces Positive NXP002 Results in Lung Tissue Models

The pharmaceutical company reports positive results from its analysis of lung tissue samples, suggesting its lead drug candidate NXP002 has potential to treat fibrotic diseases like IPF and autoimmune ILD.

NFX
NEUTRAL

Nuformix Announces Posting of Annual Report and Notice of AGM

The pharmaceutical company has posted its annual report and notice of the upcoming annual general meeting.

NFX
NEUTRAL

Nuformix Raises £168,750 Through Placing to Fund Pipeline Development

The pharmaceutical developer has announced a £168,750 placing to progress its pipeline and fund general corporate purposes. The raise represents a 17.6% dilution of existing shares, but is being conducted at a premium to the current share price.